Product information and disease description Place of product in therapy Disease description Burden of Fibrodysplasia ossificans progressiva

Economic burden and healthcare resource utilization

6 evidence topics · 4 sources

France: annual healthcare expenditure 10 to 14 times higher than matched controls

“Mean total annual healthcare expenditure was more than 10 times greater in individuals with FOP than those without FOP from a societal perspective (largely driven by outpatient costs) and 14 times greater from a payer perspective.” (opens the source at this quote in a new tab)
“Consultations with general practitioners and non-physician healthcare providers, hospitalizations, and use of medical devices and treatments were significantly greater in individuals with vs without FOP (p < .05 for all).” (opens the source at this quote in a new tab)

France: costs by disability severity and age

“Mean total expenditures for individuals with no identified severity were €3152 compared with €11 820 for individuals with high disability severity level (p = .0002)” (opens the source at this quote in a new tab)
“Outpatient costs were the only societal cost category to increase significantly with age (<10 yr, €1399; >30 yr, €7438; p = .0133).” (opens the source at this quote in a new tab)
“Total societal costs were largely driven by outpatient costs, of which medical devices were the most expensive component (mean annual cost: €1761).” (opens the source at this quote in a new tab)

China: annual cost per patient of USD 10,820, mostly indirect

“The average total annual cost was $10,820 ± 10,894, of which indirect and direct non-medical costs accounted for 75.2% ($8,134 ± 7,978) and 21.6% ($2,332 ± 7,374), respectively (Fig. 2).” (opens the source at this quote in a new tab)
“In the past year, up to 61.2% of patients had neither outpatient nor inpatient visits due to FOP. Only 14.9% of patients had hospital admissions, with an annual average of 1.8 ± 1.6 hospitalizations per patient.” (opens the source at this quote in a new tab)

United States: out-of-pocket cost of care by mobility level

“Additionally, while costs appear to plateau for patients with PRMA total scores in Levels 3 and 4, at a mean of approximately 22,000 U.S. dollars, the range of costs becomes progressively wider with each PRMA level; patients with PRMA total scores in Level 4 reported an upper range of approximately 164,000 U.S. dollars for costs related to FOP.” (opens the source at this quote in a new tab)
“Living adaptations related to mobility, daily activities, and/or pay for assistance constituted the greatest overall costs for U.S. patients compared with the other four categories of living adaptations assessed (Supplementary Table S9).” (opens the source at this quote in a new tab)

Healthcare services and assistive devices used

“The healthcare services most commonly consulted by patients with FOP in the 12 months prior to survey completion were general practitioners (GP; 78.3%) and dentists/orthodontists (59.5%), with healthcare service utilization varying by the patient’s PRMA level (Figure 5(a)).” (opens the source at this quote in a new tab)
“Overall, financial costs limited or prevented nearly half (47.7%) of patients with FOP from traveling (Supplementary Table S8).” (opens the source at this quote in a new tab)

In-hospital outcomes among FOP hospitalizations compared with matched controls in Switzerland

Outcome	FOP hospitalizations	Matched comparators	Relative risk or change (95% CI)
Length of hospital stay, days, median (IQR)	“5.5 (3-13)”	“3 (2-5.75)”	“2.04 (1.58, 2.62)”
ICU admission, n (%)	“10 (16.1)”	“19 (6.1)”	“2.63 (1.29, 5.38)”
In-hospital mortality, n (%)	“1 (1.6)”	“5 (1.6)”	“1.00 (0.12, 8.41)”
30-day readmission, n (%)	“9 (14.5)”	“18 (5.8)”	“2.50 (1.18, 5.30)”